Armata Pharmaceuticals, Inc. (ARMP) Financial Ratios
32 years of historical data (1993–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 2.99
30Y Low0.4·High132.5
ROE
↓
N/A
—
5yr avg: -949.2%
30Y Low-332%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Armata Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $40M | $67M | $117M | $43M | $132M | $49M | $26M | $4M | $6M | $4M | $22M |
| Enterprise Value | $157M | $184M | $224M | $76M | $160M | $52M | $23M | $-4226160 | $1M | $-579060 | $12M |
| P/E Ratio → | -20.97 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.68 | 12.93 | 25.81 | 7.72 | 29.52 | 59.53 | — | — | 56.10 | 16.65 | 45.34 |
| P/B Ratio | — | — | — | 1.18 | 5.20 | 2.60 | 1.78 | 0.46 | 0.83 | 0.45 | 1.69 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 35.59 | 49.40 | 13.89 | 35.72 | 63.79 | — | — | 11.47 | -2.23 | 25.61 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Armata Pharmaceuticals, Inc. earns an operating margin of -820.2%. Operating margins have compressed from -670.8% to -820.2% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -565.4% | -565.4% | 78.5% | -535.7% | -347.4% | -1655.0% | — | — | -225.2% | -41.9% | 100.0% |
| Operating Margin | -820.2% | -820.2% | -902.8% | -670.8% | -532.5% | -2623.0% | — | — | -14048.7% | -8991.5% | -2153.1% |
| Net Profit Margin | -365.6% | -365.6% | -1524.5% | -670.2% | -517.5% | -2695.1% | — | — | -11163.5% | -7245.4% | -108.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -3439.4% | -120.1% | -104.6% | -132.6% | -168.9% | -149.5% | -147.1% | -167.9% | -6.4% |
| ROA | -20.5% | -20.5% | -67.0% | -41.6% | -42.4% | -68.3% | -104.3% | -105.2% | -87.5% | -75.8% | -1.7% |
| ROIC | -44.2% | -44.2% | -42.4% | -45.0% | -47.4% | -95.9% | -243.9% | -644.2% | -326.9% | -429.8% | -7670.3% |
| ROCE | -70.7% | -70.7% | -49.6% | -49.9% | -48.7% | -80.9% | -127.7% | -135.5% | -135.9% | -106.9% | -36.6% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $117M ($127M total debt minus $9M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 1.35 | 1.50 | 0.70 | 0.20 | — | — | 0.08 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 0.94 | 1.09 | 0.19 | -0.22 | -0.96 | -0.66 | -0.50 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.95 | -3.95 | -15.57 | -1274.00 | -372.22 | -34.37 | -20.50 | — | — | — | — |
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.23x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.09x to 0.23x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.23 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 3.27 | 2.74 | 1.78 | 4.20 |
| Quick Ratio | 0.23 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 3.27 | 2.74 | 1.95 | 4.20 |
| Cash Ratio | 0.19 | 0.19 | 0.82 | 0.60 | 2.14 | 1.44 | 1.24 | 3.17 | 2.61 | 1.60 | 3.93 |
| Asset Turnover | — | 0.06 | 0.05 | 0.05 | 0.06 | 0.02 | — | — | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 52.49 | 271.03 | 128.29 | 243.85 | 248.80 | — | — | — | 35.10 | 96.05 |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Armata Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 1.8% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 0.0% |
| Shares Outstanding | — | $36M | $36M | $34M | $24M | $16M | $8M | $1M | $456244 | $70275 | $38651 |
Peer Comparison
Compare ARMP with 7 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARMPYou | $40M | -21.0 | — | — | -565.4% | -820.2% | — | -44.2% | — |
 MCRB | $77M | -0.5 | — | — | — | — | 1.0% | -180.9% | — |
 PHGE | $76M | -2.9 | — | — | — | — | -130.2% | -305.2% | — |
 EVGN | $7M | -0.3 | — | — | 39.8% | -255.4% | -75.8% | -102.4% | — |
 SYBX | $7M | -0.3 | — | — | 100.0% | -511875.0% | -84.3% | -205.7% | — |
 TOVX | $2M | -0.0 | — | — | — | — | -87.3% | -142.7% | — |
 AZTR | $2M | -0.1 | — | — | — | — | -0.6% | -0.8% | — |
 ELAB | $766221 | -0.0 | — | — | 72.8% | -75.7% | -119.1% | -82.7% | — |
| Healthcare Median | — | 23.3 | 13.6 | 18.1 | 66.0% | -6.6% | -36.9% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See ARMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARMP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARMP vs MCRB
See how ARMP stacks up against sector leader Seres Therapeutics, Inc..
Start ComparisonFrequently Asked Questions
What is Armata Pharmaceuticals, Inc.'s P/E ratio?
Armata Pharmaceuticals, Inc.'s current P/E ratio is -21.0x. This places it at the 50th percentile of its historical range.
Is ARMP stock overvalued?
Based on historical data, Armata Pharmaceuticals, Inc. is trading at a P/E of -21.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Armata Pharmaceuticals, Inc.'s profit margins?
Armata Pharmaceuticals, Inc. has -565.4% gross margin and -820.2% operating margin.